Protara Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$64.5M | -$49.2M | -$43.6M | -$67.1M | -$47.5M |
| Operating expenses | $64.5M | $49.2M | $43.6M | $67.1M | $47.5M |
| Cash from operations | -$56.4M | -$35.8M | -$37.6M | -$26.5M | -$34.5M |
| Capital expenditure | $94,000 | $63,000 | $45,000 | $120,000 | $596,000 |
| Free cash flow | -$56.5M | -$35.9M | -$37.6M | -$26.6M | -$35.1M |
| Share repurchases | — | — | $91,000 | $90,000 | $228,000 |
| Impairments | — | — | — | $29.5M | — |
| Total assets | $209.5M | $181.5M | $79.0M | $113.3M | $172.6M |
| Total liabilities | $13.1M | $14.3M | $10.6M | $11.2M | $10.7M |
Shares outstanding 56.2M · Free float 83.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.